Veracyte Inc. (VCYT)
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
VCYT stays on investors radar due to the strong performance of the Afirma and Decipher franchises.
Veracyte Gains 44% in a Year: What's Driving the Stock?
VCYT is gaining shares due to the strength of its Afirma and Decipher tests.
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
Veracyte's progress with key drivers and the strength in its diagnostics tests bring optimism to investors.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates
Veracyte (VCYT) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago.
Veracyte: Revolutionizing Noninvasive Cancer Diagnostics
In this ROBO Global Artificial Intelligence Index spotlight, we focus on Veracyte (VCYT). The index underlies the $137 million ROBO Global Artificial Intelligence ETF (THNQ).
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veracyte (VCYT) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Veracyte, Inc. (VCYT) could be a good stock pick from a technical perspective. VCYT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
